Ascendis Pharma A/S Overview
Pro stress-test →Ascendis Pharma is a Danish biopharmaceutical company founded in 2007 that develops TransCon-based therapies for endocrinology and rare diseases. The company applies its proprietary TransCon technology platform to create potentially best-in-class treatments addressing unmet medical needs globally, with particular focus on growth disorders, hypoparathyroidism, and other endocrine conditions.
Strategic Profile
Pro stress-test →Ascendis is rapidly transforming into a leading global biopharma with maturing commercial infrastructure supported by strong R&D capabilities and validated clinical success. The company leverages strategic partnerships and licensing agreements with pharmaceutical leaders (Novo Nordisk, Teijin Limited) and maintains significant equity stakes in specialized subsidiaries (VISEN Pharmaceuticals 39%, Eyconis 41%) to expand its therapeutic reach across multiple markets.
Competitive Landscape
Pro stress-test →Ascendis competes in the biopharmaceutical space primarily against other endocrinology and rare disease developers. Main competitors include Novo Nordisk (partnered on semaglutide collaboration), Versartis (growth hormone therapies), Ultragenyx (rare genetic diseases), and Regeneron (specialty therapeutics). Ascendis differentiates through its proprietary TransCon platform enabling once-weekly or less frequent dosing versus conventional therapies.
Industry Context
Ascendis Pharma A/S operates in Biopharmaceutical / Specialty Pharma - Endocrinology & Rare Diseases.
Key facts
Founded: 2007 · Headquarters: Hellerup, Denmark · Employees: 1,017 · Revenue: $393.4M (2024) · Market cap: $13.7B